Top entities: Pacira BioSciences, eVenus.

What category does this event fall under?

Regulatory — classified as securities lawsuit.

What is the sentiment of coverage?

Aggregate sentiment score: -70 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Is this event still developing?

This event is archived — the story has concluded and this page is a final snapshot.

Regulatory securities lawsuit

Pacira BioSciences Patent Invalidity Lawsuit

Q: When did this event occur?

First reported Feb 03, 2025; last updated Feb 13, 2025.

Q: What is the market impact?

General. The invalidation of Pacira BioSciences's key patent for Exparel, which accounts for 80% of its revenue, caused its stock to drop over 47% in a single day.

Q: What were the key actions taken?

Pacira BioSciences filed lawsuit eVenus

Analysis based on 11 articles · First reported Feb 03, 2025 · Last updated Feb 13, 2025

Sentiment

-70

Attention

Articles

Market Impact

General

Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

Market Impact

The invalidation of Pacira BioSciences's key patent for Exparel, which accounts for 80% of its revenue, caused its stock to drop over 47% in a single day. This event could lead to increased generic competition and litigation expenses for Pacira BioSciences, negatively impacting its future market position and investor confidence.

Pharmaceuticals Biotechnology

Event Summary

Pacira BioSciences's U.S. Patent No. 11,033,495 for its drug Exparel, a major revenue source, was found invalid by a court on August 9, 2024, in a lawsuit against eVenus. This ruling led to a dramatic decline of over 47% in Pacira BioSciences's stock price on August 9, 2024. Analysts suggest this invalidation could question the validity of other patents held by Pacira BioSciences, potentially opening the market to more generic entrants and increasing future litigation costs. The Gross Law Firm has subsequently issued notices to shareholders, encouraging them to join a securities class action lawsuit against Pacira BioSciences, with a deadline for lead plaintiff appointment set for March 14, 2025.

Key Actions

90 Pacira BioSciences filed lawsuit eVenus

Entities Involved

stock

Pacira BioSciences

Pacira BioSciences faces a securities class action lawsuit after its key patent for Exparel was found invalid, leading to a significant stock price decline and potential market entry for generic competitors.

Importance 100.0 Sentiment -80.0

oth

eVenus

eVenus was the defendant in a patent infringement lawsuit brought by Pacira BioSciences, which eVenus won, leading to the invalidation of Pacira BioSciences's patent.

Importance 60.0 Sentiment 50.0

ERGEN INTELLIGENCE

Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard